We are live on ! Find out more
LEXXW

Lexaria Bioscience Warrant
LEXXW

Delisted

LEXXW was delisted on the 13th of January, 2026.

Back to rankings

5 hedge funds and large institutions have $593K invested in Lexaria Bioscience Warrant in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more funds holding

Funds holding: 4 → 5 (+1)

26% less capital invested

Capital invested by funds: $802K → $593K (-$209K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

Holders
5
Holders Change
+1
Holders Change %
+25%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$930

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$72.1K
2
EAM
Empery Asset Management
New York
-$3.91K
3
CH
CVI Holdings
Delaware
-$2.63K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$240K -$72.1K -82,349 -19%
BFM
2
Boothbay Fund Management
New York
$235K – – –
EAM
3
Empery Asset Management
New York
$88K -$3.91K -4,467 -3%
CH
4
CVI Holdings
Delaware
$29K -$2.63K -3,000 -7%
UBS Group
5
UBS Group
Switzerland
$1K +$930 +1,061 New

LEXXW Hedge Fund Activity: Q2 2022 in Review

5 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience Warrant (LEXXW) for Q2 2022, worth a combined $593K — down 26% from $802K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new LEXXW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 3 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $930. The largest seller was Sabby Management, cutting an estimated $72.1K.

  • 5 institutional investors held Lexaria Bioscience Warrant (LEXXW) as of Q2 2022, up from 4 in Q1 2022.
  • Funds reported $593K of Lexaria Bioscience Warrant stock for Q2 2022, down 26% quarter-over-quarter.
  • 1 fund opened new Lexaria Bioscience Warrant positions in Q2 2022 and 0 closed out, a net change of +1 holder.
  • The largest Lexaria Bioscience Warrant buyer in Q2 2022 was UBS Group, an estimated $930 added.
  • The largest Lexaria Bioscience Warrant seller in Q2 2022 was Sabby Management, an estimated $72.1K sold.

Based on aggregated 13F filings for Q2 2022.